Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Korade M 3rd"'
Autor:
Cannon DA; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Cambridge, United Kingdom., Shan L; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, United States of America., Du Q; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, United States of America., Shirinian L; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, United States of America., Rickert KW; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, United States of America., Rosenthal KL; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, United States of America., Korade M 3rd; Department of Oncology Research, AstraZeneca, Gaithersburg, Maryland, United States of America., van Vlerken-Ysla LE; Department of Oncology Research, AstraZeneca, Gaithersburg, Maryland, United States of America., Buchanan A; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Cambridge, United Kingdom., Vaughan TJ; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Cambridge, United Kingdom., Damschroder MM; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, United States of America., Popovic B; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Cambridge, United Kingdom.
Publikováno v:
PLoS computational biology [PLoS Comput Biol] 2019 May 01; Vol. 15 (5), pp. e1006980. Date of Electronic Publication: 2019 May 01 (Print Publication: 2019).
Autor:
Cho S; MedImmune, Gaithersburg, Maryland. chos@medimmune.com francesca.zammarchi@adctherapeutics.com., Zammarchi F; ADC Therapeutics (UK) Limited, London, United Kingdom. chos@medimmune.com francesca.zammarchi@adctherapeutics.com., Williams DG; Spirogen, London, United Kingdom., Havenith CEG; ADC Therapeutics (UK) Limited, London, United Kingdom., Monks NR; MedImmune, Gaithersburg, Maryland., Tyrer P; Spirogen, London, United Kingdom., D'Hooge F; Spirogen, London, United Kingdom., Fleming R; MedImmune, Gaithersburg, Maryland., Vashisht K; MedImmune, Gaithersburg, Maryland., Dimasi N; MedImmune, Gaithersburg, Maryland., Bertelli F; Spirogen, London, United Kingdom., Corbett S; Spirogen, London, United Kingdom.; University College London, London, United Kingdom., Adams L; Spirogen, London, United Kingdom., Reinert HW; University College London, London, United Kingdom., Dissanayake S; ADC Therapeutics (UK) Limited, London, United Kingdom., Britten CE; ADC Therapeutics (UK) Limited, London, United Kingdom., King W; MedImmune, Gaithersburg, Maryland., Dacosta K; MedImmune, Gaithersburg, Maryland., Tammali R; MedImmune, Gaithersburg, Maryland., Schifferli K; MedImmune, Gaithersburg, Maryland., Strout P; MedImmune, Gaithersburg, Maryland., Korade M 3rd; MedImmune, Gaithersburg, Maryland., Masson Hinrichs MJ; MedImmune, Gaithersburg, Maryland., Chivers S; ADC Therapeutics (UK) Limited, London, United Kingdom., Corey E; University of Washington, Seattle, Washington., Liu H; Department of Urology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York., Kim S; Department of Urology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York., Bander NH; Department of Urology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York., Howard PW; Spirogen, London, United Kingdom., Hartley JA; Spirogen, London, United Kingdom.; University College London, London, United Kingdom., Coats S; MedImmune, Gaithersburg, Maryland., Tice DA; MedImmune, Gaithersburg, Maryland., Herbst R; MedImmune, Gaithersburg, Maryland., van Berkel PH; ADC Therapeutics (UK) Limited, London, United Kingdom.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2018 Oct; Vol. 17 (10), pp. 2176-2186. Date of Electronic Publication: 2018 Jul 31.
Autor:
Harper J; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland. harperja@medimmune.com., Lloyd C; Antibody Discovery and Protein Engineering, MedImmune, Ltd, Cambridge, United Kingdom., Dimasi N; Antibody Discovery and Protein Engineering, MedImmune, LLC, Gaithersburg, Maryland., Toader D; Antibody Discovery and Protein Engineering, MedImmune, LLC, Gaithersburg, Maryland., Marwood R; Antibody Discovery and Protein Engineering, MedImmune, Ltd, Cambridge, United Kingdom., Lewis L; Antibody Discovery and Protein Engineering, MedImmune, Ltd, Cambridge, United Kingdom., Bannister D; Antibody Discovery and Protein Engineering, MedImmune, Ltd, Cambridge, United Kingdom., Jovanovic J; Antibody Discovery and Protein Engineering, MedImmune, Ltd, Cambridge, United Kingdom., Fleming R; Antibody Discovery and Protein Engineering, MedImmune, LLC, Gaithersburg, Maryland., D'Hooge F; Spirogen, London, United Kingdom., Mao S; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Marrero AM; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Korade M 3rd; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Strout P; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Xu L; Antibody Discovery and Protein Engineering, MedImmune, LLC, Gaithersburg, Maryland., Chen C; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Wetzel L; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Breen S; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., van Vlerken-Ysla L; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Jalla S; Project Management, MedImmune, LLC, Gaithersburg, Maryland., Rebelatto M; Pathology, MedImmune, LLC, Gaithersburg, Maryland., Zhong H; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Hurt EM; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Hinrichs MJ; Biologics Safety Assessment, MedImmune, LLC, Gaithersburg, Maryland., Huang K; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Howard PW; Spirogen, London, United Kingdom., Tice DA; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Hollingsworth RE; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Herbst R; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland., Kamal A; Oncology Research, MedImmune, LLC, Gaithersburg, Maryland.; Ferring Pharmaceuticals, San Diego, California.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2017 Aug; Vol. 16 (8), pp. 1576-1587. Date of Electronic Publication: 2017 May 18.